| Year |
Citation |
Score |
| 2023 |
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath Iii CA, Gien LT, Hinchcliff EM, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. The New England Journal of Medicine. PMID 36972022 DOI: 10.1056/NEJMoa2302312 |
0.327 |
|
| 2023 |
Tewari KS, Sill MW, Birrer MJ, Penson RT, Huang H, Moore DH, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical Cancer: A NRG oncology randomized study. Gynecologic Oncology. 171: 141-150. PMID 36898292 DOI: 10.1016/j.ygyno.2023.01.010 |
0.343 |
|
| 2020 |
Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, et al. . Molecular Cancer Therapeutics. PMID 32847980 DOI: 10.1158/1535-7163.Mct-20-0276 |
0.386 |
|
| 2020 |
Tewari KS, Sill MW, Coleman RL, Aghajanian C, Mannel R, DiSilvestro PA, Powell M, Randall LM, Farley J, Rubin SC, Monk BJ. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecologic Oncology. PMID 32723679 DOI: 10.1016/J.Ygyno.2020.07.015 |
0.467 |
|
| 2020 |
Zamarin D, Burger RA, Sill MW, Powell DJ, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902059. PMID 32275468 DOI: 10.1200/Jco.19.02059 |
0.536 |
|
| 2020 |
Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, ... Sill MW, et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 32114513 DOI: 10.1136/Ijgc-2019-000869 |
0.484 |
|
| 2019 |
Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecologic Oncology. PMID 31623857 DOI: 10.1016/J.Ygyno.2019.09.024 |
0.383 |
|
| 2018 |
Matulonis UA, Sill MW, Makker V, Mutch DG, Carlson JW, Darus CJ, Mannel RS, Bender DP, Crane EK, Aghajanian C. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 30587441 DOI: 10.1016/J.Ygyno.2018.12.008 |
0.521 |
|
| 2018 |
Tew WP, Sill MW, Walker JL, Secord AA, Bonebrake AJ, Schilder JM, Stuckey A, Rice L, Tewari KS, Aghajanian CA. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology. PMID 30177462 DOI: 10.1016/J.Ygyno.2018.08.027 |
0.535 |
|
| 2018 |
Richardson DL, Coleman RL, Sill MW. Paclitaxel and Pazopanib in Ovarian Cancer-Reply. Jama Oncology. PMID 29978183 DOI: 10.1001/Jamaoncol.2018.1712 |
0.431 |
|
| 2018 |
Longoria T, Sill M, Monk B, Fruehauf J, Liao S, Emerson R, Kim J, Mannel R, Lee Y, Mathews C, Randall L, Darcy K, Birrer M, Tewari K. GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study Gynecologic Oncology. 149: 37-38. DOI: 10.1016/J.Ygyno.2018.04.084 |
0.411 |
|
| 2017 |
Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, et al. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. Jama Oncology. PMID 29242937 DOI: 10.1001/Jamaoncol.2017.4218 |
0.397 |
|
| 2017 |
Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet (London, England). PMID 28756902 DOI: 10.1016/S0140-6736(17)31607-0 |
0.47 |
|
| 2017 |
Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28756871 DOI: 10.1016/J.Ygyno.2017.07.135 |
0.552 |
|
| 2017 |
Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA, Spirtos NM, Byron J, Thaker PH, Lele S, et al. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28285845 DOI: 10.1016/J.Ygyno.2017.02.040 |
0.458 |
|
| 2017 |
Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, Backes F, Tenney ME, Mathews CA, Hoffman JS, Aghajanian C, Hensley ML. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecologic Oncology. 144: 96-100. PMID 28094040 DOI: 10.1016/J.Ygyno.2016.10.036 |
0.484 |
|
| 2016 |
Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27217446 DOI: 10.1200/Jco.2015.65.8153 |
0.434 |
|
| 2016 |
Matulonis U, Sill M, Thaker P, Carlson J, Darus C, Mannel R, Bender D, Higgins R, Aghajanian C. NRG/GOG 186K: A randomized phase II study of NCI-supplied cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer—Final results Gynecologic Oncology. 141: 207. DOI: 10.1016/J.Ygyno.2016.04.533 |
0.475 |
|
| 2016 |
Rader J, Sill M, Garcia F, Beumer J, Benbrook D, Zuna R, Spirtos N, Hamilton C, Lele S, Byron J, Alberts D, Trimble C. A stratified randomized double-blind phase II trial of celecoxib in the treatment of patients with cervical intraepithelial neoplasia: A Gynecologic Oncology Group (GOG 0207) study with translational biomarkers and drug level monitoring Gynecologic Oncology. 141: 21. DOI: 10.1016/J.Ygyno.2016.04.079 |
0.465 |
|
| 2016 |
Cohn D, Sill M, Walker J, O'Malley D, Nagel C, Rutledge T, Bradley W, Richardson D, Moxley K, Aghajanian C. GOG 186H: A randomized phase II evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin) in the treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer Gynecologic Oncology. 141: 6-7. DOI: 10.1016/J.Ygyno.2016.04.042 |
0.54 |
|
| 2016 |
Westin S, Sill M, Coleman R, Waggoner S, Moore K, Mathews C, Jain A, Modesitt S, Schilder R, Aghajanian C. Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study Gynecologic Oncology. 141: 4-5. DOI: 10.1016/J.Ygyno.2016.04.038 |
0.426 |
|
| 2015 |
Tewari KS, Sill MW, Monk BJ, Penson RT, Long HJ, Poveda A, Landrum LM, Leitao MM, Brown J, Reid TJ, Michael HE, Moore DH. Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 5480-7. PMID 26672085 DOI: 10.1158/1078-0432.Ccr-15-1346 |
0.511 |
|
| 2015 |
Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 138: 507-12. PMID 26186911 DOI: 10.1016/J.Ygyno.2015.04.018 |
0.549 |
|
| 2015 |
Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecologic Oncology. 138: 513-8. PMID 26171911 DOI: 10.1016/J.Ygyno.2015.07.006 |
0.442 |
|
| 2015 |
McMeekin DS, Sill MW, Walker JL, Moore KN, Waggoner SE, Thaker PH, Rizack T, Hoffman JS, Fracasso PM. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 138: 36-40. PMID 25958319 DOI: 10.1097/01.Ogx.0000471706.11154.3B |
0.503 |
|
| 2015 |
Coleman RL, Sill MW, Thaker PH, Bender DP, Street D, McGuire WP, Johnston CM, Rotmensch J. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 138: 30-5. PMID 25887099 DOI: 10.1016/J.Ygyno.2015.04.005 |
0.494 |
|
| 2015 |
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 137: 386-91. PMID 25818403 DOI: 10.1016/J.Ygyno.2015.03.042 |
0.469 |
|
| 2015 |
Hyman DM, Sill M, Cho JK, Lankes HA, Piekarz R, Hensley ML. A phase II study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-0231D). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16512 |
0.398 |
|
| 2015 |
Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study Gynecologic Oncology. DOI: 10.1016/j.ygyno.2015.07.018 |
0.472 |
|
| 2015 |
Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial Gynecologic Oncology. DOI: 10.1016/j.ygyno.2015.07.006 |
0.406 |
|
| 2015 |
Moore K, Sill M, Tenney M, Darus C, Griffin D, Werner T, Waggoner S, Behrens R. A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study Gynecologic Oncology. 137: 24. DOI: 10.1016/J.Ygyno.2015.01.055 |
0.49 |
|
| 2015 |
Tewari K, Sill M, Monk B, Penson R, Lankes H, Leitao M, Ramondetta L, Van Le L, Richardson D, Landrum L, DiSilvestro P, Behbakht K, Ueland F, Michael H, Birrer M. Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: An NRG Oncology/Gynecologic Oncology Group study Gynecologic Oncology. 137: 12. DOI: 10.1016/J.Ygyno.2015.01.026 |
0.41 |
|
| 2014 |
Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. 135: 441-5. PMID 25312396 DOI: 10.1016/J.Ygyno.2014.10.001 |
0.545 |
|
| 2014 |
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. 135: 38-43. PMID 25019571 DOI: 10.1016/J.Ygyno.2014.07.083 |
0.51 |
|
| 2014 |
Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. Gynecologic Oncology. 133: 433-8. PMID 24708919 DOI: 10.1016/J.Ygyno.2014.03.571 |
0.563 |
|
| 2014 |
Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. The New England Journal of Medicine. 370: 734-43. PMID 24552320 DOI: 10.1056/NEJMoa1309748 |
0.357 |
|
| 2014 |
Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 132: 526-30. PMID 24361733 DOI: 10.1016/J.Ygyno.2013.12.018 |
0.534 |
|
| 2014 |
Tew WP, Sill M, McMeekin DS, Secord AA, Bonebrake AJ, Schilder J, Stuckey A, Rice L, Tewari KS, Aghajanian C. A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC). Journal of Clinical Oncology. 32: 5546-5546. DOI: 10.1200/Jco.2014.32.15_Suppl.5546 |
0.503 |
|
| 2014 |
Tewari K, Sill M, Penson R, Huang H, Ramondetta L, Landrum L, Oaknin A, Reid T, Leitao M, Monk B, Michael H. Final Overall Survival Analysis of the Phase III Randomized Trial of Chemotherapy with and Without Bevacizumab for Advanced Cervical Cancer: a Nrg Oncology - Gynecologic Oncology Group Study Annals of Oncology. 25: v1. DOI: 10.1093/Annonc/Mdu438.27 |
0.542 |
|
| 2014 |
Tewari K, Sill M, Moore D, Long H, Penson R, Huang H, Landrum L, Oaknin A, Michael H, Monk B, Ramondetta L, Reid T, Leitao M. High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: A Gynecologic Oncology Group (GOG) study Gynecologic Oncology. 133: 60. DOI: 10.1016/J.Ygyno.2014.03.164 |
0.425 |
|
| 2014 |
Tewari K, Sill M, Monk B, Long H, Penson R, Huang H, Landrum L, Oaknin A, Michael H, Moore D, Leitao M, Ramondetta L, Reid T. Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: A Gynecologic Oncology Group (GOG) study Gynecologic Oncology. 133: 59-60. DOI: 10.1016/J.Ygyno.2014.03.163 |
0.464 |
|
| 2014 |
Dizon D, Sill M, Schilder J, McGonigle K, Rahman Z, Miller D, Mutch D, Leslie K. Results of Gynecologic Oncology Group (GOG) 229K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma Gynecologic Oncology. 133: 55. DOI: 10.1016/J.Ygyno.2014.03.153 |
0.473 |
|
| 2014 |
Alvarez R, Sill M, Davidson S, Muller C, Bender D, DeBernardo R, Behbakht K, Huh W. A phase II trial of intraperitoneal EGEN-001, an interleukin (IL)-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: A GOG study Gynecologic Oncology. 133: 40. DOI: 10.1016/J.Ygyno.2014.03.117 |
0.482 |
|
| 2013 |
Sill M, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3. PMID 28136059 DOI: 10.1200/Jco.2013.31.15_Suppl.3 |
0.481 |
|
| 2013 |
Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 129: 486-94. PMID 23438670 DOI: 10.1016/J.Ygyno.2013.02.019 |
0.493 |
|
| 2013 |
Coleman R, Sill M, Thaker P, De Geest K, Street D, McGuire W, Rotmensch J. A phase II evaluation of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study Gynecologic Oncology. 130: e12-e13. DOI: 10.1016/J.Ygyno.2013.04.086 |
0.537 |
|
| 2013 |
Tewari K, Sill M, Monk B, Long H, Ramondetta L, Landrum L, Oaknin A, Reid T, Leitao M, Michael H. Phase III randomized clinical trial of cisplatin plus paclitaxel vs the non-platinum chemotherapy doublet of topotecan plus paclitaxel in women with recurrent, persistent, or advanced cervical carcinoma: A Gynecologic Oncology Group study Gynecologic Oncology. 130: e2. DOI: 10.1016/J.Ygyno.2013.04.060 |
0.51 |
|
| 2013 |
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. Corrigendum to “A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study” [Gynecol Oncol 127 (2012) 538–543] Gynecologic Oncology. 130: 252-253. DOI: 10.1016/J.Ygyno.2013.04.007 |
0.368 |
|
| 2012 |
Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecologic Oncology. 127: 456-61. PMID 22960004 DOI: 10.1016/j.ygyno.2012.08.030 |
0.413 |
|
| 2012 |
Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 506-10. PMID 22943879 DOI: 10.1016/j.ygyno.2012.08.037 |
0.415 |
|
| 2012 |
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 538-43. PMID 22922531 DOI: 10.1016/J.Ygyno.2012.08.020 |
0.499 |
|
| 2012 |
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecologic Oncology. 127: 345-50. PMID 22885469 DOI: 10.1016/J.Ygyno.2012.07.127 |
0.401 |
|
| 2012 |
Sill MW, Rubinstein L, Litwin S, Yothers G. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials. Clinical Trials (London, England). 9: 385-95. PMID 22811448 DOI: 10.1177/1740774512450101 |
0.397 |
|
| 2012 |
McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 356-61. PMID 22796461 DOI: 10.1016/J.Ygyno.2012.07.095 |
0.474 |
|
| 2012 |
Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecologic Oncology. 126: 375-80. PMID 22683587 DOI: 10.1016/J.Ygyno.2012.06.002 |
0.352 |
|
| 2012 |
Aghajanian C, Sill MW, Secord AA, Powell MA, Steinhoff M. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. Gynecologic Oncology. 126: 424-7. PMID 22634397 DOI: 10.1016/j.ygyno.2012.05.024 |
0.302 |
|
| 2012 |
Rose PG, Sill MW, McMeekin DS, Ahmed A, Salani R, Yamada SD, Wolfson AH, Fusco N, Fracasso PM. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecologic Oncology. 125: 158-62. PMID 22198338 DOI: 10.1016/J.Ygyno.2011.12.431 |
0.429 |
|
| 2012 |
Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 125: 54-8. PMID 22155262 DOI: 10.1016/J.Ygyno.2011.12.417 |
0.502 |
|
| 2012 |
Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology. 124: 563-8. PMID 22138229 DOI: 10.1016/J.Ygyno.2011.11.035 |
0.547 |
|
| 2012 |
Garcia AA, Sill MW, Lankes HA, Godwin AK, Mannel RS, Armstrong DK, Carolla RL, Liepman MK, Spirtos NM, Fischer EG, Leslie KK. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecologic Oncology. 124: 569-74. PMID 22037316 DOI: 10.1016/J.Ygyno.2011.10.022 |
0.529 |
|
| 2011 |
Moore KN, Sill M, Miller DS, Disilvestro P, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) women with locally advanced cervical cancer (CXCA): A GOG study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5032. PMID 28023707 DOI: 10.1200/jco.2011.29.15_suppl.5032 |
0.341 |
|
| 2011 |
Dizon DS, Sill M, Gould NS, Rubin SC, Yamada SD, DeBernardo R, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5066. PMID 28023681 DOI: 10.1200/jco.2011.29.15_suppl.5066 |
0.385 |
|
| 2011 |
Dizon DS, Sill MW, Gould N, Rubin SC, Yamada SD, Debernardo RL, Mannel RS, Eisenhauer EL, Duska LR, Fracasso PM. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecologic Oncology. 123: 182-6. PMID 21820161 DOI: 10.1016/J.Ygyno.2011.07.016 |
0.476 |
|
| 2011 |
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecologic Oncology. 123: 19-26. PMID 21752435 DOI: 10.1016/J.Ygyno.2011.06.022 |
0.399 |
|
| 2011 |
Santin AD, Sill MW, McMeekin DS, Leitao MM, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic Oncology. 122: 495-500. PMID 21684583 DOI: 10.1016/j.ygyno.2011.05.040 |
0.398 |
|
| 2011 |
Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2259-65. PMID 21537039 DOI: 10.1200/JCO.2010.32.6397 |
0.443 |
|
| 2011 |
Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecologic Oncology. 121: 455-61. PMID 21414654 DOI: 10.1016/J.Ygyno.2011.02.013 |
0.371 |
|
| 2011 |
Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecologic Oncology. 121: 303-8. PMID 21329967 DOI: 10.1016/j.ygyno.2011.01.030 |
0.301 |
|
| 2011 |
Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS. A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 121: 264-8. PMID 21277623 DOI: 10.1016/J.Ygyno.2010.12.358 |
0.411 |
|
| 2011 |
Herzog TJ, Sill MW, Walker JL, O'Malley D, Shahin M, DeGeest K, Weiner SA, Mutch D, DeBernardo RL, Lentz SS. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecologic Oncology. 120: 454-8. PMID 21168198 DOI: 10.1016/j.ygyno.2010.11.008 |
0.434 |
|
| 2011 |
Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, De Geest K, Bonebrake AJ, Walker JL. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecologic Oncology. 120: 459-63. PMID 21144560 DOI: 10.1016/J.Ygyno.2010.11.012 |
0.427 |
|
| 2011 |
Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 69-75. PMID 21098323 DOI: 10.1200/Jco.2009.26.7856 |
0.454 |
|
| 2011 |
Kunos CA, Sill MW, Buekers TE, Walker JL, Schilder JM, Yamada SD, Waggoner SE, Mohiuddin M, Fracasso PM. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 120: 224-8. PMID 21075438 DOI: 10.1016/J.Ygyno.2010.10.018 |
0.436 |
|
| 2011 |
Sill MW, Monk BJ. Comments on: "Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens" (Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch J, de Geest K, et al. Gynecol Oncol. 2011 Mar;120(3):459-63) Gynecologic Oncology. 122: 462-463. DOI: 10.1016/J.Ygyno.2011.05.026 |
0.341 |
|
| 2011 |
Chase D, Sill M, Chambers M, Darcy K, Han E, Fruehauf J, Monk B, Buening B, Sorosky J, Burger R. Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial Gynecologic Oncology. 120: S65-S66. DOI: 10.1016/J.Ygyno.2010.12.157 |
0.502 |
|
| 2010 |
Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecologic Oncology. 119: 484-90. PMID 20870280 DOI: 10.1016/J.Ygyno.2010.08.016 |
0.362 |
|
| 2010 |
Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 118: 303-7. PMID 20547415 DOI: 10.1016/J.Ygyno.2010.05.020 |
0.509 |
|
| 2010 |
Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecologic Oncology. 117: 248-54. PMID 20189232 DOI: 10.1016/j.ygyno.2010.01.002 |
0.314 |
|
| 2010 |
Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 116: 15-20. PMID 19840887 DOI: 10.1016/j.ygyno.2009.09.025 |
0.378 |
|
| 2010 |
Monk BJ, Sill M, Walker JL, Hanjani P, Edwards RP, Rotmensch J, De Geest K, Bonebrake AJ. Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG). Journal of Clinical Oncology. 28: 5046-5046. DOI: 10.1200/jco.2010.28.15_suppl.5046 |
0.484 |
|
| 2010 |
Sill MW, Fleming G. In Re: Re: "Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: A Gynecologic Oncology Group Study" Gynecologic Oncology. 118: 96-97. DOI: 10.1016/j.ygyno.2010.03.005 |
0.393 |
|
| 2009 |
Tiersten A, Sill M, Muggia F, Elera C, Garcia A, Fracasso P, Swensen R, Warshal D, Mannel R. Phase I/feasibility trial of dose-dense carboplatin (C) and paclitaxel (P) in patients (pts) with ovarian cancer: A Gynecologic Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5544. PMID 27962513 DOI: 10.1200/Jco.2009.27.15_Suppl.5544 |
0.461 |
|
| 2009 |
Sill MW, Sampson AR. Drop-the-Losers Design: Binomial Case. Computational Statistics & Data Analysis. 53: 586-595. PMID 20047003 DOI: 10.1016/J.Csda.2008.07.031 |
0.616 |
|
| 2009 |
Hensley ML, Sill MW, Scribner DR, Brown J, Debernardo RL, Hartenbach EM, McCourt CK, Bosscher JR, Gehrig PA. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecologic Oncology. 115: 460-5. PMID 19811811 DOI: 10.1016/j.ygyno.2009.09.011 |
0.331 |
|
| 2009 |
Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4649-55. PMID 19720909 DOI: 10.1200/Jco.2009.21.8909 |
0.482 |
|
| 2009 |
Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 19: 929-33. PMID 19574787 DOI: 10.1111/Igc.0B013E3181A83467 |
0.439 |
|
| 2009 |
Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1069-74. PMID 19139430 DOI: 10.1200/JCO.2008.18.9043 |
0.361 |
|
| 2008 |
Han ES, Burger R, Darcy KM, Sill MW, Greer BE, Sorosky JI, Fruehauf JP. Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5577. PMID 27950426 DOI: 10.1200/Jco.2008.26.15_Suppl.5577 |
0.414 |
|
| 2008 |
Sabbatini P, Sill MW, O'Malley D, Adler L, Secord AA. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecologic Oncology. 111: 455-60. PMID 18829087 DOI: 10.1016/j.ygyno.2008.07.049 |
0.49 |
|
| 2008 |
Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3418-25. PMID 18612157 DOI: 10.1200/Jco.2007.14.3420 |
0.521 |
|
| 2008 |
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecologic Oncology. 110: 329-35. PMID 18597837 DOI: 10.1016/J.Ygyno.2008.05.008 |
0.528 |
|
| 2008 |
Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 109: 182-6. PMID 18295319 DOI: 10.1016/J.Ygyno.2008.01.009 |
0.515 |
|
| 2008 |
Kavanagh JJ, Sill MW, Ramirez PT, Warshal D, Pearl ML, Morgan MA, Mackey D. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study International Journal of Gynecological Cancer. 18: 460-464. PMID 17854432 DOI: 10.1111/J.1525-1438.2007.01053.X |
0.527 |
|
| 2008 |
Monk BJ, Sill M, McMeekin DS, Cohn DE, Ramondetta L, Boardman CH, Benda J. A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study. Journal of Clinical Oncology. 26: LBA5504-LBA5504. DOI: 10.1200/jco.2008.26.15_suppl.lba5504 |
0.406 |
|
| 2007 |
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5165-71. PMID 18024863 DOI: 10.1200/Jco.2007.11.5345 |
0.534 |
|
| 2007 |
McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecologic Oncology. 106: 596-603. PMID 17597196 DOI: 10.1016/J.Ygyno.2007.05.013 |
0.483 |
|
| 2007 |
McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecologic Oncology. 105: 508-16. PMID 17306350 DOI: 10.1016/J.Ygyno.2007.01.019 |
0.559 |
|
| 2007 |
Sill MW, Sampson AR. Extension of a two-stage conditionally unbiased estimator of the selected population to the bivariate normal case Communications in Statistics - Theory and Methods. 36: 801-813. DOI: 10.1080/03610920601034072 |
0.526 |
|
| 2005 |
Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5539-48. PMID 16061871 DOI: 10.1158/1078-0432.Ccr-05-0462 |
0.465 |
|
| 2005 |
Sampson AR, Sill MW. Drop-the-losers design: normal case. Biometrical Journal. Biometrische Zeitschrift. 47: 257-68; discussion 2. PMID 16053251 DOI: 10.1002/Bimj.200410119 |
0.609 |
|
| Show low-probability matches. |